Annals of Nuclear Medicine最新文献

{"title":"FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?","authors":"Irene García Megías,&nbsp;Ludmila Santiago Almeida,&nbsp;Adriana K. Calapaquí Terán,&nbsp;Kim M. Pabst,&nbsp;Ken Herrmann,&nbsp;Francesco Giammarile,&nbsp;Roberto C. Delgado Bolton","doi":"10.1007/s12149-025-02022-x","DOIUrl":"10.1007/s12149-025-02022-x","url":null,"abstract":"<div><p>[¹⁸F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it is not exempt of diagnostic limitations. FAPI have emerged as a great tool in the management of several different solid tumours in which [¹⁸F]FDG is not able to provide enough information. The aim of this work was to evaluate the available evidence on diagnostic and therapeutic applications of PET/CT with FAPI radiopharmaceuticals. We underwent a non-systematic review focusing in the utility of FAPI radiopharmaceuticals in PET/CT diagnosis and in the treatment of several malignancies. FAPI radiopharmaceuticals present characteristics that can potentially overcome some known diagnostic limitations of [¹⁸F]FDG. FAPI radiopharmaceuticals present a high target-to-background ratio (TBR) in many solid tumours such as oesophageal cancer, gastric cancer, pancreatic cancer, hepatic cancer, colorectal cancer, breast cancer, ovarian, cervical cancer, and head and neck cancer. Available evidence suggests the high TBR improves sensitivity and specificity compared to [¹⁸F]FDG, especially for the detection of lymphadenopathies and peritoneal metastases, and may improve patient management and radiation treatment planning. Moreover, it is important to underline the potential theranostic application of FAPI radiopharmaceuticals.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 5","pages":"407 - 423"},"PeriodicalIF":2.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-025-02022-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into lung cancer diagnosis and clinical management using [¹⁸F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT).","authors":"Xingyu Mu, Zhuohao Zhu, Zhenzhen Wang, Xiaotian Li, Yang Wu, Jingze Li, Lei Zhang, Wei Fu","doi":"10.1007/s12149-025-02032-9","DOIUrl":"https://doi.org/10.1007/s12149-025-02032-9","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate diagnosis and staging of lung cancer are critical for optimal clinical management. Fibroblast activation protein inhibitor (FAPI) imaging has emerged as a promising modality with superior detection capabilities for lung cancer. We hypothesized that [¹⁸F]FAPI-42 PET/CT would enhance diagnosis, TNM staging, and influence oncologic management in patients with suspected or confirmed lung cancer.</p><p><strong>Methods: </strong>In this retrospective study, 155 patients with clinically suspected or confirmed lung cancer underwent both conventional imaging and [¹⁸F]FAPI-42 PET/CT scans within a one-week interval, without any intervening treatment. Lesions were visually assessed and categorized to evaluate the diagnostic capability of [¹⁸F]FAPI-42 PET/CT. Tracer activity was quantified using maximum standardized uptake values (SUV_max) and tumor-to-background ratios. TNM staging was independently determined by a board-certified radiologist or nuclear medicine physician using both imaging modalities, and discrepancies were assessed. Changes in TNM staging were documented and evaluated for their impact on clinical management.</p><p><strong>Results: </strong>Of the 155 patients, 99 were evaluated for primary lesion diagnosis and staging. Pathological examination confirmed malignant tumors in 87 patients and benign tumors in 12. The diagnostic sensitivity and positive predictive value of [¹⁸F]FAPI-42 PET/CT for detecting primary lung tumors were 96.77% and 92.78%, respectively. Malignant lesions exhibited significantly higher SUV_max compared to benign lesions (5.2 vs. 1.5, P = 0.0002), with an area under the ROC curve of 0.87. In total, 1,556 malignant lesions were identified among patients with lung cancer, and [¹⁸F]FAPI-42 PET/CT demonstrated a diagnostic accuracy of 95.50%. However, its sensitivity for detecting adrenal metastases was lower at 33.33%, with a specificity of 100% and an accuracy of 53.85%. The use of [¹⁸F]FAPI-42 PET/CT resulted in changes in TNM staging for 46% of patients, leading to upstaging in 58 patients and downstaging in 5. These staging adjustments directly impacted clinical management in 34 patients, prompting modifications in treatment plans.</p><p><strong>Conclusion: </strong>[¹⁸F]FAPI-42 PET/CT is a promising modality for lung cancer diagnosis and staging, demonstrating high sensitivity and specificity. Its use significantly altered TNM staging in nearly half of the patients, directly impacting oncologic management and treatment planning. However, its limited sensitivity for detecting adrenal metastases underscores the need for additional imaging techniques.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ga-68 Pentixafor PET/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study.","authors":"Dinesh Kumar Gauthaman, Indirani Muthukrishnan, K Ashish Acharya, Shelley Simon","doi":"10.1007/s12149-025-02036-5","DOIUrl":"https://doi.org/10.1007/s12149-025-02036-5","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the role of Ga-68 Pentixafor PET/CT in staging and follow-up of multiple myeloma (MM) and its correlation with clinical parameters.</p><p><strong>Methods: </strong>Thirteen participants (9 males, 4 females; median age: 65 years) with MM were recruited in this prospective observational study. Six participants were included for staging evaluation, seven were included for follow-up evaluation, and underwent Ga-68 Pentixafor PET/CT. Focal PET-positive bone marrow lesions or diffuse bone marrow uptake (uptake more than liver) was considered a positive scan. The quantitative variables like SUVmax, SUVmean, total bone marrow volume and uptake (TBMV & TBMU) and tumor to background ratio (TBRmax) were obtained. Durie Salmon Plus Staging (DSPS) was used for MM staging by PET/CT and was compared with the International Staging System (ISS). Statistical comparison was performed between PET/CT quantitative variables and laboratory parameters.</p><p><strong>Results: </strong>Twelve participants (12/13) had positive Ga-68 Pentixafor PET/CT, among which one was diagnosed to have anemia of chronic disease. One participant (1/13) who was clinically negative on follow-up had negative Ga-68 Pentixafor PET/CT. The sensitivity, specificity, PPV and NPV of Ga-68 Pentixafor PET/CT in MM (95% CI) were observed to be 100%, 50%, 91.6% and 100%, respectively. The correlation between DSPS and ISS in the patients who came for staging scans was found to be statistically significant (p-value 0.02). In quantitative analysis, either of the quantitative variables in Ga-68 Pentixafor PET/CT was positively correlated with clinical parameters related to tumor burden like CRAB score, serum protein electrophoresis M-protein, beta 2 microglobulin, LDH, percentage of plasma cells infiltrates in bone marrow aspiration, ISS, serum free light chain and negatively correlated with hemoglobin, albumin (p < 0.5).</p><p><strong>Conclusion: </strong>Ga-68 Pentixafor PET/CT is a promising tracer and the only available non-invasive tool to assess the whole-body disease burden of CXCR4 receptors in staging and follow-up of MM. In addition, it has a vital role in the development of CXCR4-targeted theranostics. Dual tracer imaging using F-18 FDG and Ga-68 Pentixafor PET/CT may help in evaluating tumor heterogeneity in MM and add prognostic value at diagnosis and follow-up.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of [⁶⁸Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis.","authors":"Yuriko Mori, Katharina Tamburini, Emil Novruzov, Dominik Schmitt, Eleni Mavriopoulou, Sven H Loosen, Christoph Roderburg, Tadashi Watabe, Clemens Kratochwil, Manuel Röhrich, Abass Alavi, Uwe Haberkorn, Frederik L Giesel","doi":"10.1007/s12149-025-02027-6","DOIUrl":"https://doi.org/10.1007/s12149-025-02027-6","url":null,"abstract":"<p><strong>Introduction: </strong>Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix. Early detection has a great clinical impact because 80-90% of hepatocellular carcinomas are known to develop in fibrotic or cirrhotic (end-stage fibrotic) livers. PET imaging with FAP ligands exhibited highly promising results in recent years to visualize fibrosis in various organs due to the crucial role of activated fibroblasts in fibrosing processes. However, still little is known about the efficacy of FAP imaging in liver fibrosis. Thus, we sought to investigate the potential of FAPI-PET in a cohort of oncological and non-oncological patients.</p><p><strong>Methods: </strong>199 patients who underwent FAPI-PET/CT at the University Hospital of Heidelberg between July 2017 and July 2020 were retrospectively analyzed. The tracer uptake of the liver was analyzed and correlated with radiological and clinical parameters.</p><p><strong>Results: </strong>We observed a weak but significant negative correlation between the hepatic FAPI uptake and CT density (r = - 0.273, P < 0.001***). A positive correlation was observed between hepatic FAPI uptake and the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) (r = 0.183, P = 0.009**), an established surrogate for liver fibrosis. The liver SUV (standardized uptake value) mean and SUVmax of FAPI showed significant differences between groups of patients with low (< 0.5), middle (0.5-1.0) and higher (> 1.0) levels of APRI (both P < 0.001***).</p><p><strong>Conclusion: </strong>These preliminary observational results suggest that FAPI-PET may be a viable non-invasive method to asses liver fibrosis.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating second primary lung cancer from pulmonary metastasis in patients of single solitary pulmonary lesion with extrapulmonary tumor using multiparametric analysis of FDG PET/CT.","authors":"Honghong Liu, Xiaolin Meng, Guanyun Wang, Shulin Yao, Yanmei Wang, Ruimin Wang, Tao Wang","doi":"10.1007/s12149-025-02034-7","DOIUrl":"https://doi.org/10.1007/s12149-025-02034-7","url":null,"abstract":"<p><strong>Objective: </strong>Using fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT), a multiparametric analysis will be performed in the differential diagnosis of patients with single solitary pulmonary lesion and extrapulmonary malignant tumor to discriminate between a second primary lung cancer (SPLC) and pulmonary metastasis (PM).</p><p><strong>Methods: </strong>This study retrospectively studied 84 patients with preoperative exams utilizing ¹⁸F-FDG PET/CT. Using complementing PET/CT parameters, a composite model was developed. A receiver operating characteristic (ROC) analysis assessed the combined model and each independent parameter's differential diagnostic efficacies. Furthermore, this study investigated the improvement in diagnostic efficacy using other metrics, such as integrated discriminatory improvement (IDI) and net reclassification improvement (NRI).</p><p><strong>Results: </strong>The highest discriminative diagnostic value was obtained by the independent parameters energy (1,039,358.1 [95126.2-1,965,032.2] vs. 92,011.0 [45916.3-365,322.9], P = 0.001). In comparison to peak standardized uptake value (SUVpeak), total lesion glycolysis (TLG), energy, lobulation, and spiculation alone, the combined model (addition of these factors) significantly improved the differential diagnostic efficacy of SPLCs and PMs (sensitivity = 76.2%, specificity = 83.8%, area under the curve [AUC] = 0.826) and permitted reclassification using IDI = 0.176 (P < 0.001), 0.169 (P < 0.001), 0.127 (P < 0.001), and categorical NRI = 0.678 (P < 0.001), 0.637 (P < 0.001), and 0.592 (P < 0.001) compared to SUVpeak, TLG and energy separately. DeLong's test revealed a statistically significant enhancement in ROC when compared to SUVpeak (Z = 2.372, P = 0.018), TLG (Z = 2.095, P = 0.036), and energy (Z = 2.318, P = 0.020).</p><p><strong>Conclusion: </strong>Combining multiple parameters using ¹⁸F-FDG PET/CT may further improve distinguishing between SPLCs and PMs in patients with single solitary pulmonary lesion and extrapulmonary malignant tumor.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics of lung ventilation/perfusion tomographic imaging in pulmonary embolism diagnosis.","authors":"Yu-Shuang Liu, Lei Wang, Hao-Yu Song, Li Wang, Yuan-Hua Yang, Qi Yang, Juan-Ni Gong, Min-Fu Yang","doi":"10.1007/s12149-025-02037-4","DOIUrl":"https://doi.org/10.1007/s12149-025-02037-4","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to develop a machine learning model (named V/P-mics) to identify pulmonary embolism based on lung ventilation/perfusion single-photon emission tomography (V/P-SPECT) images.</p><p><strong>Methods: </strong>We retrospectively collected the data of 260 patients from one hospital who underwent V/P-SPECT. Patients were randomly assigned to training and testing groups in a 7:3 ratio. We created an internal further validation group using data of an additional 35 patients from the same hospital, and an external further validation group using data of 30 patients from another hospital. We constructed 35 models and selected one for further optimization. The generalizability of V/P-mics was proven by comparing the area under the curve (AUC) of the testing group, internal and external further validation groups. The diagnostic accuracy and efficiency of V/P-mics was compared with that of nuclear physicians.</p><p><strong>Results: </strong>V/P-mics showed excellent generalizability, with no statistical difference in AUC among the testing, internal further validation, and external further validation groups (0.938 vs. 0.923 vs. 0.990, all P values > 0.05). The AUC of V/P-mics was close to that of the senior physician (0.923 vs. 0.975, P = 0.332), but significantly higher than the junior physician (0.923 vs. 0.725, P = 0.050). Furthermore, V/P-mics significantly shortened the diagnosis time as compared to the junior physician (100 ± 16 s vs. 240 ± 37 s, P = 0.001).</p><p><strong>Conclusion: </strong>The V/P-mics had good discrimination and generalizability and significantly shortened the diagnosis time for patients with pulmonary embolism. Of note, the model showed excellent interpretability.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A low-dose protocol in pediatric ¹⁸F-FDG scans using 30-cm axis field of view PET/CT.","authors":"Ha Wu, Guobing Liu, Xiemei Ruan, Biying Zhang, Zheng Zhe, Hongcheng Shi","doi":"10.1007/s12149-025-02030-x","DOIUrl":"https://doi.org/10.1007/s12149-025-02030-x","url":null,"abstract":"<p><strong>Objective: </strong>To explore the feasibility of a low-dose ¹⁸F-FDG protocol for the 30-cm standard axial field of view (SAFOV) PET/CT imaging in pediatric patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 112 pediatric patients who underwent a full-dose (3.7 MBq/kg) ¹⁸F-FDG PET/CT imaging, and a prospective analysis was performed on 55 patients who received a low-dose (2.5 MBq/kg) imaging. PET images were reconstructed at 1.0-min/bed intervals, and labeled as G1.0, G2.0, G3.0 for the full-dose imaging and G1.0', G2.0', G3.0' for the low-dose imaging. Patients were categorized into three age groups, and the image quality was assessed using the Likert scale and signal-to-noise ratio (SNR); Lesion detectability was evaluated using lesion detection rates and the target-to-liver ratio (TLR).</p><p><strong>Results: </strong>In G2.0 and G3.0, all cases (112/112) achieved an image score of ≥ 3 and a lesion detection rate of 100% (98/98). There were no significant differences in SNR between G2.0 and G3.0 (11.09 ± 2.31 vs. 11.88 ± 2.58, p = 0.39), nor between age groups ≤ 5 years and 6-10 years groups (9.52 ± 3.16 vs. 9.53 ± 3.19, p = 0.99). In G3.0', 98.2% of cases (54/55) had an image score ≥ 3 and a lesion detection rate of 100% (43/43). The SNR of every age group for G3.0' was comparable to that of G2.0, and no significant differences between ≤ 5 years and 6-10 years groups (9.32 ± 1.94 vs. 9.99 ± 2.28, p = 0.82).</p><p><strong>Conclusions: </strong>A 2.5 MBq/kg dose with a 3.0 min/bed acquisition protocol is feasible for ¹⁸F-FDG 30-cm SAFOV PET/CT imaging in pediatric patients, and SNR and TLR demonstrated age-dependent discrepancies.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotype-specific metabolic patterns in Posterior cortical atrophy and early-onset typical Alzheimer’s disease","authors":"Jiaying Lu,&nbsp;Keliang Chen,&nbsp;Huamei Lin,&nbsp;Zizhao Ju,&nbsp;Jingjie Ge,&nbsp;Jie Lu,&nbsp;Yihui Guan,&nbsp;Qihao Guo,&nbsp;Shuguang Chu,&nbsp;Qianhua Zhao,&nbsp;Chuantao Zuo,&nbsp;Ping Wu,&nbsp;for the Shanghai Memory Study","doi":"10.1007/s12149-025-02025-8","DOIUrl":"10.1007/s12149-025-02025-8","url":null,"abstract":"<div><h3>Objective</h3><p>Posterior cortical atrophy (PCA) is generally considered an atypical variant of Alzheimer's disease (AD) and is an important component of early-onset AD. Symptomatologic heterogeneity has led to a high rate of misdiagnosis or delayed diagnosis of early-onset AD. We sought to establish the phenotypic-specific metabolic patterns of PCA and early-onset typical AD (tAD) and to assess whether phenotype-specific neuroimaging biomarkers are more valuable for disease recognition.</p><h3>Methods</h3><p>Patients accepting ¹⁸F-FDG PET with an onset age younger than 65 years (PCA, <i>n</i> = 40; early-onset tAD, <i>n</i> = 37; behavioral variant frontotemporal dementia (bv-FTD), <i>n</i> = 35) and healthy controls (HCs, <i>n</i> = 30) were enrolled and divided into two cohorts for pattern establishment and validation, respectively. Similarities and differences between patterns were assessed by pattern topography, expression, classification performance and correlation with clinical severity.</p><h3>Results</h3><p>PCA-related pattern (PCARP) was characterized by extensively relative hypometabolism in the parietal lobe, occipital lobe, temporal lobe, cingulate gyrus, and relative hypermetabolism mainly in vermis, thalamus. Early-onset tAD-related pattern (EOtADRP) was characterized by relative hypometabolism mainly in the middle frontal gyrus, angular gyrus, precuneus, middle temporal gyrus, cingulate gyrus, caudate, and relative hypermetabolism mainly in vermis, thalamus, postcentral gyrus. PCARP and EOtADRP were closely related in topography (<i>r</i> = 0.909, <i>P</i> &lt; 0.001) and expression (<i>r</i> = 0.862, <i>P</i> &lt; 0.001). High accuracies in distinguishing corresponding patient group from HC were found in both, while only PCARP was capable of phenotype discrimination (PCA <i>versus</i> early-onset tAD; area under the receiver operating characteristic curve [AUC] = 0.84–0.88 for PCARP, AUC = 0.57–0.62 for EOtADRP) and distinguishment between PCA/early-onset tAD and bv-FTD (AUC = 1.00/0.91 for PCARP, AUC = 0.73/0.62 for EOtADRP). PCARP showed great potential in detecting clinical severity in both phenotypes whereas EOtADRP only worked in early-onset tAD.</p><h3>Conclusion</h3><p>PCARP outperformed EOtADRP in phenotype discrimination with better potential in severity assessment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 5","pages":"506 - 517"},"PeriodicalIF":2.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there any effect of hcc location on selective internal radiation therapy with 90yttrium response?","authors":"Elife Akgun,&nbsp;Cagrı Erdim,&nbsp;Burcu Ibicioglu,&nbsp;Tevfik Guzelbey,&nbsp;Burcu Esen Akkas,&nbsp;Ozgur Kılıckesmez","doi":"10.1007/s12149-025-02028-5","DOIUrl":"10.1007/s12149-025-02028-5","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;We planned this retrospective study to evaluate the effect of the central vs peripheral location effect on the success of selective internal radiation therapy (SIRT) with &lt;sup&gt;90&lt;/sup&gt;Yttrium-90 (&lt;sup&gt;90&lt;/sup&gt;Y) glass microspheres in hepatocellular carcinomas (HCC).&lt;/p&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;p&gt;Thirty-eight patients diagnosed with HCC who were eligible for SIRT with &lt;sup&gt;90&lt;/sup&gt;Y glass microspheres were included in this study. The location being central versus peripheral was defined as explained: Straight lines through the bifurcation of the right and left branches of the portal vein to the center of the HCC and the peripheral surface of the liver were traced on the same plane. The coefficient was determined as a ratio of the center of the HCC to the distance from the hilum of the liver at the portal vein bifurcation. Value under ½ accepted as central location (Group 1, &lt;i&gt;n&lt;/i&gt; = 17), over ½ values are accepted as peripheral location (Group 2, &lt;i&gt;n&lt;/i&gt; = 21). Treatment responses were analyzed after 2 months of the treatment with magnetic resonance imaging, and 2-deoxy-2-[&lt;sup&gt;18&lt;/sup&gt;F]fluoro-D-glucose positron emission tomography/computed tomography ([&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT) for FDG-avid ones. Differences in treatment responses rates, treatment approach, the absorbed doses and the volumes of each liver segments between groups were investigated.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;In Group 1; mean age was 67. In 5 cases split infusion, in 10 cases tumor selective treatment approach were applied. According to PERCIST/mRECIST criteria treatment responses categories: complete response in 2/1 cases, partial response in 7/9 cases, stable disease in 3/4 cases, progressive diseases in 2/3 cases; respectively. AFP value decreased in 2 cases, increased in 7 cases, and was stable in 1 case. Mean absorbed doses were 347.9 Gy for tumor, 140.6 Gy for perfused normal tissue, and 26.1 Gy for the normal liver. In Group 2; the mean age was 71.5. In 5 cases split infusion, and in 1 case non-selective treatment approach were applied. According to PERCIST/mRECIST criteria treatment responses categories: complete response in 7/6 cases, partial response in 7/10 cases, stable disease in 2/2 cases, and progressive diseases in 3/3 cases; respectively. AFP value decreased in 9 cases, increased in 2 cases, and was stable in 2 cases. Mean absorbed doses were 495.9 Gy for tumor, 134 Gy for perfused normal tissue, and 17.3 Gy for the normal liver.There is no statistically significant difference in terms of gender, treatment response rates, tumor volumes, perfuse tissue volumes between 2 groups. However, tumor-selective approach and absorbed doses of the perfused normal tissue and the tumor were significantly higher in Group 2 (&lt;i&gt;p&lt;/i&gt; = 0.007, 0.04, and 0.02; respectively).&lt;/p&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Contrary to expectation, centrally located HCCs could be treated as successfully as peripherally located HCCs. However, the complete response rate in the p","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 5","pages":"527 - 534"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-025-02028-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis.","authors":"Jingjia Cao, Xiang Li, Huazhen Liang, Yang Li, Fei Zhao, Aiqiang Dong","doi":"10.1007/s12149-025-02029-4","DOIUrl":"https://doi.org/10.1007/s12149-025-02029-4","url":null,"abstract":"<p><strong>Objective: </strong>Compared with those of sporadic differentiated thyroid cancer (SDTC), the tumor characteristics of familial nonmedullary thyroid cancer (FNMTC) remain debatable. In addition, there is a paucity of data suggesting that their response to radioactive iodine (RAI) therapy differs from that of SDTC. We aimed to determine whether FNMTC is a homogenous biological entity that differs from SDTC in RAI therapy.</p><p><strong>Methods: </strong>We retrospectively analyzed patients who underwent adjuvant ablative iodine radiotherapy between July 2016 and March 2020. We compared the differences in clinicopathological features and prognoses between the FNMTC and SDTC groups. The endpoint of the study was the rate of therapeutic response after 1 and 3 years of follow-up after first-line treatment. The response to therapy was classified into four categories: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR) and indeterminate response (IDR). In addition, we conducted a meta-analysis of cohort studies to investigate the clinical outcomes.</p><p><strong>Results: </strong>Of all the patients (n = 1758), 109 (6.2%) were classified as having FNMTC, whereas the remaining 1649 (93.8%) had SDTC. A greater proportion of FNMTC patients presented with extrathyroidal extension, capsular invasion, and multifocality (P = 0.01). In addition, patients with FNMTC were more likely to have advanced primary tumor stage and lymph node metastasis, but the differences were not statistically significant. At the end of follow-up (median follow-up of 3 years), the response to RAI therapy was significantly different between the two groups (ER: 66.1% vs 74.3%; IDR: 9.2% vs 12.1%; SIR: 14.7% vs 7.1%; BIR: 10.1% vs 6.5%). Moreover, patients with FNMTC more frequently presented evidence of disease than patients with SDTC did. However, the disease-free survival of patients with FNMTC was not shorter than that of patients with SDTC (P ≥ 0.05).</p><p><strong>Conclusion: </strong>Patients with FNMTC more often have aggressive characteristics at presentation and relatively worse clinical outcomes after RAI therapy. However, there was no statistically significant difference in the recurrence rate in the short-term follow-up. Considering that, FNMTC patients may be required more aggressive treatment approaches and closer postoperative monitoring.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}